Clazosentan Sodium

N/A

Report date: 2023/12/08 16:06:50
NME

Base Information

Drug NameClazosentan Sodium
Drug Alias Nameclazosentanum克拉生坦clazosentanPivlazRo-61-1790 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin receptor type A antagonists
TargetsEndothelin receptor type A
Therapy Area/IndicationsAneurysmVasospasm, IntracranialSubarachnoid Hemorrhage +[5] 
Global Approved IndicationsVasospasm, IntracranialSubarachnoid HemorrhageCerebral Infarction +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2022/01/20
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIdorsia Pharmaceuticals Ltd
Inactive CompaniesPatheon Uk LtdActelion Pharmaceuticals Ltd
Active IndicationsAneurysmVasospasm, IntracranialSubarachnoid Hemorrhage +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG